Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, Tassone P, Francini G, Tagliaferri P. Correale P, et al. Among authors: licchetta a. J Immunother. 2010 May;33(4):435-41. doi: 10.1097/CJI.0b013e3181d32f01. J Immunother. 2010. PMID: 20386463 Free PMC article. Clinical Trial.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Correale P, et al. Among authors: licchetta a. Cancer Biol Ther. 2010 May 1;9(9):685-93. doi: 10.4161/cbt.9.9.11441. Cancer Biol Ther. 2010. PMID: 20697196 Clinical Trial.
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.
Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P. Correale P, et al. Among authors: licchetta a. Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142823 Clinical Trial.
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.
Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P. Correale P, et al. Among authors: licchetta a. J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004. J Immunother. 2014. PMID: 24316553 Clinical Trial.
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Correale P, et al. Among authors: licchetta a. Cancer Biol Ther. 2011 Jul 15;12(2):112-8. doi: 10.4161/cbt.12.2.15722. Epub 2011 Jul 15. Cancer Biol Ther. 2011. PMID: 21525780 Clinical Trial.
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors. Petrioli R, et al. Among authors: licchetta a. Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380. Cancer Invest. 2012. PMID: 22236191
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.
Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, Roviello G, Martellucci I, Chiriacò G, Miano ST, Marzocca G, Manganelli A, Ponchietti R, Savelli V, Petrioli R. Francini F, et al. Among authors: licchetta a. Prostate Cancer. 2011;2011:258689. doi: 10.1155/2011/258689. Epub 2011 Aug 21. Prostate Cancer. 2011. PMID: 22096653 Free PMC article.
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, Pisconti S, Petrelli F, Vacca A, Lorusso V. Gnoni A, et al. Among authors: licchetta a. Crit Rev Oncol Hematol. 2015 Jul;95(1):46-61. doi: 10.1016/j.critrevonc.2015.01.008. Epub 2015 Jan 20. Crit Rev Oncol Hematol. 2015. PMID: 25656744 Review.
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.
Perri F, Pisconti S, Conson M, Pacelli R, Della Vittoria Scarpati G, Gnoni A, D'Aniello C, Cavaliere C, Licchetta A, Cella L, Giuliano M, Schiavone C, Falivene S, Di Lorenzo G, Buonerba C, Ravo V, Muto P. Perri F, et al. Among authors: licchetta a. Onco Targets Ther. 2015 Jun 8;8:1345-9. doi: 10.2147/OTT.S75232. eCollection 2015. Onco Targets Ther. 2015. PMID: 26089683 Free PMC article.
19 results